Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) (2022)
- Authors:
- USP affiliated authors: ZUARDI, ANTONIO WALDO - FMRP ; GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; SOUZA, JOSÉ DIOGO RIBEIRO DE - FMRP ; PACHECO, JÚLIA COZAR - FMRP ; ROSSI, GIORDANO NOVAK - FMRP
- Unidade: FMRP
- DOI: 10.3390/pharmaceutics14122598
- Subjects: CANABINOIDES; INTERAÇÃO DE MEDICAMENTOS; ENSAIO CLÍNICO CONTROLADO RANDOMIZADO; MEDICAMENTO
- Keywords: Cannabidiol; CBD; Safety; Adverse effects; Drug interaction
- Language: Inglês
- Imprenta:
- Source:
- Título: Pharmaceutics
- ISSN: 1999-4923
- Volume/Número/Paginação/Ano: v. 14, art. 2598, p. 1-14, 2022
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
SOUZA, José Diogo Ribeiro de et al. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, v. 14, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14122598. Acesso em: 07 abr. 2026. -
APA
Souza, J. D. R. de, Pacheco, J. C., Rossi, G. N., Paulo, B. O. de, Zuardi, A. W., Guimarães, F. S., et al. (2022). Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, 14, 1-14. doi:10.3390/pharmaceutics14122598 -
NLM
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2026 abr. 07 ] Available from: https://doi.org/10.3390/pharmaceutics14122598 -
Vancouver
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2026 abr. 07 ] Available from: https://doi.org/10.3390/pharmaceutics14122598 - Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
- Cannabidiol as a treatment for mental health outcomes among health care workers during the coronavirus disease pandemic. [Carta]
- Cannabidiol for the treatment of epilepsy: an overview of possible mechanisms of action and preclinical and human studies
- Cannabidiol for the treatment of drug use disorders
- Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: a mechanistic overview
- Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
- The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
- Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
- Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning?
- Effects of minocycline on regional cerebral blood flow in schizophrenia
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003153761.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
